[The study on the assessment of the new levodopa drug--stalevo (levodopa/carbidopa/entacapone), in treatment of Parkinson's disease in out-patient clinical practice (the results of the open START-M)].
Despite significant symptomatic effect of levodopa, in most patients the stable 24 hour's effect changed for alterations of movement symptoms (fluctuations, dyskinesia) after 2-3 years of the therapy. These complications may be reduced due to the constant (physiologic) stimulation of post-synaptic dopamine receptors that, to a certain degree, provides the drug stalevo, which contains levodopa and 2 enzyme inhibitors, dopa decarboxylase (carbidopa) and catechol-O-methyltransferase (entacapone). The results of the study demonstrated beneficial effects of stalevo as compared to traditional therapy in patients with "wearing off" and "on-off" phenomena.
Boĭko
A N
AN
Batysheva
T T
TT
Minaeva
N G
NG
Babina
L A
LA
Vdovichenko
T V
TV
Zhuravleva
E Iu
EIu
Shikhkerimov
R K
RK
Malykhina
E A
EA
Khozova
A A
AA
Zaĭtsev
K A
KA
Kostenko
E V
EV
D000203:Activities of Daily Living; D000368:Aged; D000554:Ambulatory Care Facilities; D002230:Carbidopa / Q000008:administration & dosage*; D002396:Catechols / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage*; D008297:Male; D010045:Outpatients; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
D002396:Catechols; D004338:Drug Combinations; C481098:Stalevo; D007980:Levodopa; D002230:Carbidopa